# Govt Caps Anti-Cancer Drugs Trade Margins at 30% of MRP

> Government to cap anti-cancer drug trade margins at 30% of MRP to reduce prices.
- Title: Govt Caps Anti-Cancer Drugs Trade Margins at 30% of MRP
- Summary: Government to cap anti-cancer drug trade margins at 30% of MRP to reduce prices. The Indian government plans to cap trade margins for non-scheduled…
- Keywords: india, anti-cancer-drugs, trade-margins, mrp, nppa, dghs, drug-price-control, cancer-treatment, Govt, Caps, Anti-Cancer, Drugs
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/govt-prepares-to-cap-anti-cancer-drugs-trade-margins-at-30-of-mrp/articleshow/134795010.cms
- Author: Teena Thacker
- Published: 2026-10-08T16:05:00+00:00
- Read time: 1 min
- Topics: india, anti-cancer-drugs, trade-margins, mrp, nppa, dghs, drug-price-control, cancer-treatment
## Government Prepares Trade Margin Cap
The government is preparing to identify anti-cancer medicines for a proposed 30% trade-margin cap under the Drug Price Control Order.
## NPPA Analysis Shows High Markups
NPPA analysis found non-scheduled anti-cancer medicines carry an average trade mark-up of 170%, with mark-ups reaching up to 700% in some cases.
## Expert Committee Deadline
An expert committee under DGHS will submit its report by October 14 to recommend anti-cancer drugs covered under the trade margin rationalisation.
## Trade Margin Rationalisation
The NPPA approved in principle the proposal to cap trade margins at 30% for identified non-scheduled anti-cancer medicines under Paragraph 19 of the Drug Price Control Order.
## Market Impact and Savings
The proposed exercise is expected to reduce MRP by 20, 70% and generate annual savings of around Rs 2,500 crore.
## Benefits for Patients
The move aims to reduce patients' out-of-pocket expenditure, improve affordability, curb excessive trade mark-ups, and increase price transparency.
## Key takeaway

The Indian government plans to cap trade margins for non-scheduled anti-cancer drugs at 30% of MRP to lower patient costs and curb excessive markups.